Hypertensive nephrosclerosis

Pathophysiology - Pressure Cooker Kidneys

• Chronic systemic hypertension transmits excessive pressure to unprotected renal arterioles, especially the afferent arteriole.
• This leads to endothelial injury and leakage of plasma proteins into the vessel walls.

• Histology:
  • Hyaline arteriolosclerosis: Homogeneous, pink, glassy thickening of arteriolar walls.
  • Fibroelastic hyperplasia: "Onion-skinning" in larger vessels (seen in malignant HTN).

⭐ The earliest and most significant vascular changes occur in the afferent arterioles, as they are not well-protected from high systemic pressures.

Clinical Presentation & Diagnosis - The Silent Saboteur

• Insidious Onset: Often asymptomatic for years; typically discovered incidentally on routine labs.
• Hallmark: Long-standing, poorly controlled hypertension (often >10-15 years).
• Associated Findings:
  • Signs of hypertensive end-organ damage:
    • Left Ventricular Hypertrophy (LVH).
    • Hypertensive retinopathy (AV nicking, copper wiring).
  • Slowly progressive ↑ serum creatinine & ↓ GFR.
• Urinary Findings:
  • Proteinuria: Mild (<1 g/day), non-nephrotic.
  • Urinalysis: Bland sediment, few hyaline casts.
• Imaging:
  • Ultrasound: Normal or symmetrically small, echogenic kidneys.
  • 
• Diagnosis of Exclusion: Must rule out other primary kidney diseases.

⭐ Kidney biopsy, rarely performed, classically shows hyaline arteriolosclerosis of afferent arterioles and fibroelastic hyperplasia of interlobular arteries.

Histopathology - Microscopic Mayhem

• Vascular Changes (Arterionephrosclerosis)

  • Hyaline arteriolosclerosis: Eosinophilic, homogenous thickening of small arteries & arterioles (especially afferent), leading to luminal narrowing.
  • Fibroelastic hyperplasia: Intimal thickening in larger interlobular and arcuate arteries.

• Glomerular Ischemia

  • Wrinkling and thickening of capillary basement membranes.
  • Progressive collapse of the glomerular tuft, leading to focal or global glomerulosclerosis.

• Tubulointerstitial Damage

  • Patchy tubular atrophy and interstitial fibrosis secondary to chronic ischemia.

⭐ In contrast, malignant hypertension features hyperplastic arteriolosclerosis (“onion-skinning”) and fibrinoid necrosis of arterioles, indicating acute, severe endothelial injury.

Management - Pressure Under Control

• Primary Goal: Aggressive blood pressure control to slow CKD progression.

• Target: BP < 130/80 mmHg. For patients with proteinuria >300 mg/day, a target of < 120/80 mmHg may be considered.

• First-line Therapy: ACE inhibitors (e.g., Lisinopril) or ARBs (e.g., Losartan).

  • These agents reduce systemic BP and preferentially dilate the efferent arteriole, ↓ intraglomerular pressure and ↓ proteinuria.

• Second-line Agents:

  • Thiazide diuretics (e.g., Hydrochlorothiazide) or Calcium Channel Blockers (e.g., Amlodipine) are added if BP remains above target.

⭐ ACE inhibitors and ARBs are the cornerstone of therapy, not just for BP control, but for their direct renoprotective effects by reducing glomerular hypertension.

High‑Yield Points - ⚡ Biggest Takeaways

• Caused by chronic, poorly controlled hypertension, leading to progressive renal damage.
• A major cause of end-stage renal disease (ESRD), especially in African Americans.
• Key pathology includes hyaline arteriolosclerosis of small arteries and focal global glomerulosclerosis.
• Kidneys are typically symmetrically small and shrunken with a granular surface.
• Urinalysis is often bland with absent or mild proteinuria (<1 g/day).
• Treatment is centered on strict blood pressure control, with ACE inhibitors or ARBs as first-line agents.